Novartis Appoints New CEO
Novartis has appointed Dr. Vasant Narasimhan as CEO.
On Sept. 4, 2017, Novartis announced the appointment of Vasant Narasimhan, MD, as CEO of Novartis by its board of directors, effective Feb. 1, 2018. Dr. Narasimhan currently acts as the company’s global head of drug development, chief medical officer, and a member of the executive committee.
Dr. Narasimhan, who has been with the company since 2005, will replace Joseph Jimenez. Jimenez, who served in the position for 8 years, will be available for advising until his retirement on Aug. 31, 2018.
Source: Novartis
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
